Dicot initiates first studies in disease animal models

Press release: Uppsala, March 24, 2021. The potency drug developer Dicot has for the first time initiated studies in animals with erectile dysfunction. In earlier studies, the company's drug candidate has only been tested on healthy animals. The new studies are an important step in gaining approval for clinical trials in humans.

In the past year, Dicot has conducted animal studies in collaboration with the French contract laboratory Pelvipharm, where the drug candidate LIB-01's effect on erectile function in healthy rats was tested. As previously reported, the company has been able to demonstrate that treatment with LIB-01 showed good effect in these animals, which has been confirmed in several trials.

Before starting clinical Phase 1 studies, it is important that you in the preclinical animal testing try to mimic the situation in humans as much as possible since this is where the substance ultimately should have an effect. An established way to do this is moving from healthy animals to perform studies of the effect and side effects of LIB-01 in animals with a proven erectile dysfunction. Therefore, Pelvipharm and Dicot have now decided to move on to the next level in the pharmacological evaluation and conduct studies in rats suffering from Diabetes Type 2 with a proven erectile dysfunction.

There is a clear link between erectile dysfunction and a damaged metabolic system, which leads to cardiovascular diseases and diabetes. The chosen animal model are rats that have Type 2 diabetes and impaired erectile function.

"Over the years, we have conducted several studies in healthy animals, both in the very early research and in the current preclinical testing. Now, it will be exciting to take the next step. We look forward to expand our knowledge of LIB-01 through these studies, this will take us closer to the goal of helping men suffering from sexual dysfunctions ", says Dicot's CEO, Göran Beijer.

For further information, please contact:

Göran Beijer, CEO

Phone: +46 (0) 706 63 60 09

Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion.

Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,600 shareholders. For more information, please visit www.dicot.se